The cell reprogramming market size is estimated to be USD 376.2 million in 2022 and is expected to witness a CAGR of 8.54% during the forecast period 2023-2033. Developments in stem cell biology and regenerative medicine that can offer effective treatments and expanding applications of cell reprogramming in the healthcare field are factors contributing to the market growth. Furthermore, new market players entering the marketplace and growing investments made in this area by governments and private entities is expected to support the marker growth. However, is expected to hinder the growth.

Growing investments made in this area by governments and private entities is anticipated to propel the market. For instance, the U.K.-based Mogrify start-up raised an additional USD15.61 million for its Series A financing in May 2019. For the treatment of retinal degeneration, a form of blindness, Mogrify focuses in developing medicines and reprogramming human cells. Additionally, it is anticipated that the pharmaceutical sector would make extensive use of the iPSC technique to produce useful cell sources, such as iPSC-derived functional cells, to enable drug screening and toxicity evaluation, which will boost demand for cell reprogramming technology.

To fulfil the expanding demand and pursue unexplored market opportunities, new market players entering the marketplace with advanced technology. For instance, in January 2020, Astellas Pharma, Inc. and Allele Biotechnology & Pharmaceuticals, Inc., through its subsidiary Astellas Institute for Regenerative Medicine (AIRM), entered into a licensing deal to raise the focus on developing the company’s core competency in reprogramming somatic cells into iPSCs. To fully understand the unique potential of iPSC, Allele’s researchers and the cGMP team are committed to developing and validating cell assays for product quality control, genomic analysis workflows, closed-system technology for reprogramming, and machine learning.

Segmentation

By Technology

The market is categorized into mRNA reprogramming, sendai virus-based reprogramming, episomal reprogramming, and others. In 2022, the mRNA reprogramming segment accounted for the highest revenue share due to the fact that this technology is simple to use and provides a quick, safe, and efficient way to produce the highest-quality human iPS cells from somatic tissue. For instance, cell reprogramming with synthetic mRNA is a precise and safe way to produce human iPSCs, according to a February 2021 publication. Sendai virus-based reprogramming is expected to grow at substantially during the forecast period. It is frequently used in clinical trials of gene therapy and vaccine delivery as it promotes cell reprogramming at a constant rate and has technological advantages over alternative techniques.

By Application

The market is categorized into therapeutic and research. In the global market, the research segment accounted for the largest revenue share in 2022 owing to ongoing study of stem cells-assisted cell reprogramming. Governments and other private organisations are financing a significant amount of stem cell research projects, which is driving market players to build out niches in the global market by treating a variety of chronic diseases. For instance, 64% of Americans favour federal funding for studies using human embryonic stem cells to treat chronic diseases. Therefore, it is projected that research initiatives will support segment expansion.

By End User

The market is segmented into biotechnology & pharmaceutical companies, research & academic institutes, and hospitals & clinics. In 2022, the research & academic institutes segment accounted for the largest revenue share owing to rising demand for customized medications and the economically advantageous use of bio-drugs using this technology. The use of cell reprogramming in numerous academic and clinical applications, including disease modelling, drug toxicity/drug discovery studies, regenerative medicine, and others, is fuelling the market to expand. Rise in the number of strategic initiatives for research and method for improved products from cell reprogramming is also anticipated to propel the segment. For instance, The California Institute for Regenerative Medicine has pushed numerous research organisations to provide funding for the development of therapeutic applications and a clinical focus for cellular reprogramming.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cell reprogramming market and is expected to maintain its dominance during the forecast period. This is attributed to the significant growth in iPSC technology and the accessibility of functional cells for pre-clinical drug testing. The region is growing as a result of high throughput drug toxicity analysis and growing iPSC platform knowledge. The increasing demand for novel treatment alternatives has spurred medical research activity in the United States. This enlarged study has favoured the need for cell reprogramming considering stem cell research is one of the key areas of focus. For instance, Ncardia announced the launch of a new company named Cellistic in April 2022 to support the growth of the iPSC reprogramming industry. Its focus on and expertise in differentiation, iPSC reprogramming, and other fields contribute to market expansion.

Asia Pacific is projected to be the market with the fastest growth owing to due to advancements in production and the effectiveness of the therapy landscape. As a result of the rising use of cell reprogramming technology, the sector is expanding. Additionally, the improvement of healthcare systems and the development of medical development frameworks in developing countries like Australia and India have positioned the Asia Pacific region for profitable growth during the forecast future.

Competitor Insights

Some of the key players operating in the cell reprogramming market are Alstem, Mogrify, Applied Biological Materials, Creative Bioarray, Axol Bioscience, DefiniGEN, Allele Biotechnology, Stemnovate, Lonza, Reprocell, Fujifilm Cellular Dynamics, and Thermo Fisher Scientific.

To increase their market position, major players are implementing numerous strategies into practise, such as partnerships through mergers and acquisitions, geographic growth, and strategic alliances.

• For instance, Tidal Therapeutics was obtained by Sanofi in April 2021. The latest technological platform will also improve Sanofi’s research capabilities in immuno-oncology and inflammatory disorders, and it is projected to be broadly applicable to additional disease areas.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including technology, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Cell Reprogramming Market Report 2022 – 2033

Technology (Revenue, USD Million), 2022 – 2033

• mRNA Reprogramming
• Sendai virus-based Reprogramming
• Episomal Reprogramming
• Others

Application (Revenue, USD Million), 2022 – 2033

• Therapeutic
• Research

End user (Revenue, USD Million), 2022 – 2033

• Biotechnology & Pharmaceutical Companies
• Research & Academic Institutes
• Hospitals & Clinics

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA